AlzeCure Pharma Investor Relations Material
Latest events
Status Update
AlzeCure Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from AlzeCure Pharma
Access all reports
AlzeCure Pharma AB (publ), a clinical-stage biopharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease; ACD857, ACD679 and ACD680 for Alzheimer's disease; ACD440 and TrkA-NAM for neuropathic pain; and DBS-10134 (ACD423) for migraine headache.
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden